Spyre Therapeutics Inc

Spyre Therapeutics reports promising Q1 2025 financial results and announces plans to initiate Phase 2 studies for its lead candidate, SPY001, in ulcerative colitis and rheumatoid arthritis.

Spyre Therapeutics announces positive updates on its lead candidate SPY001, a novel antibody for inflammatory bowel disease, with promising pharmacokinetic and pharmacodynamic results supporting its potential as a best-in-class treatment.